ID: ALA280817

Max Phase: Preclinical

Molecular Formula: C26H35O6P

Molecular Weight: 474.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCCOP(=O)(O)c1cc(OCc2ccccc2)ccc1/C=C/C(=O)O

Standard InChI:  InChI=1S/C26H35O6P/c1-2-3-4-5-6-7-8-12-19-32-33(29,30)25-20-24(17-15-23(25)16-18-26(27)28)31-21-22-13-10-9-11-14-22/h9-11,13-18,20H,2-8,12,19,21H2,1H3,(H,27,28)(H,29,30)/b18-16+

Standard InChI Key:  FXGSGUUTVKDHHH-FBMGVBCBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 474.53

Molecular Weight (Monoisotopic): 474.2171

AlogP: 6.33

#Rotatable Bonds: 16

Polar Surface Area: 93.06

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 2.18

CX Basic pKa:

CX LogP: 6.67

CX LogD: 1.03

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.17

Np Likeness Score: 0.12

References

1. Garigipati RS, Seibel G, Mayer RJ, Bolognese B, McCord M, Marshall LA, Adams JL.  (1997)  Novel frameworks for trifluoromethyl ketone and phosphonate tsa inhibitors of type II PLA2,  7  (11): [10.1016/S0960-894X(97)00246-1]

Source

Source(1):

• Scientific Literature